Timulak Ladislav, Keogh Daragh, McElvaney James, Schmitt Sonja, Hession Natalie, Timulakova Katarina, Jennings Ciaran, Ward Fiona
School of Psychology, Trinity College Dublin, Dublin, 2, Ireland.
Institute of Emotion-Focused Therapy Ireland, Dublin, 2, Ireland.
HRB Open Res. 2020 Feb 13;3:7. doi: 10.12688/hrbopenres.12993.1. eCollection 2020.
Depression, anxiety and related disorders, including obsessive-compulsive disorders and trauma/stressor related disorders, have high prevalence, chronic courses and cause significant impairment. These disorders are also highly co-morbid, and appear to share etiology and maintenance factors. Recent developments have seen the emergence of transdiagnostic approaches that systematically address the common/shared features of these disorders. A key advantage of transdiagnostic approaches is that they can reduce the pressure on mental health professionals to be proficient in a plethora of single-disorder focused treatments. Currently almost all transdiagnostic approaches come from cognitive-behavioural therapy (CBT). However, not all clients prefer or benefit from CBT. Emotion-focused therapy (EFT) represents an evidence-based alternative to CBT. This study aims to examine a transdiagnostic adaptation of EFT (EFT-T) as a treatment for depression, anxiety and related disorders. The current study is a randomised controlled trial that aims to establish the efficacy of EFT-T vs. wait-list control in the treatment of depression, anxiety and related disorders. Up to 40 clients presenting in a psychology/counselling service will be randomly assigned to two conditions: EFT-T (n=20) and wait-list control, with delayed intervention (n=20). Primary outcome measures will be the Overall Anxiety Severity and Impairment Symptoms, the Overall Depression Severity and Impairment Symptoms, and the Clinical Outcome in Routine Evaluation - Outcome Measure. Disorder specific self-report measures will also be used to assess the main symptomatology of respective primary diagnoses. Clients will be assessed prior to therapy, at week 16, at end of therapy, and at 6 months follow-up. This study aims to provide an initial test of EFT-T as a transdiagnostic treatment for depression, anxiety and related disorders. It will provide estimates of effects sizes that can inform power calculations for a comparative trial, comparing EFT-T to a standard transdiagnostic treatment, CBT. ISRCTN11430110; registered on 07 January 2019.
抑郁症、焦虑症及相关障碍，包括强迫症和创伤/应激源相关障碍，具有高患病率、慢性病程，并会导致严重损害。这些障碍还具有高度共病性，且似乎共享病因和维持因素。最近的发展出现了跨诊断方法，该方法系统地解决了这些障碍的共同/共享特征。跨诊断方法的一个关键优势在于，它们可以减轻心理健康专业人员精通大量单一障碍聚焦治疗的压力。目前，几乎所有跨诊断方法都来自认知行为疗法（CBT）。然而，并非所有客户都喜欢CBT或能从CBT中受益。聚焦情绪疗法（EFT）是CBT的一种循证替代方法。本研究旨在检验EFT的跨诊断适应性疗法（EFT-T）作为治疗抑郁症、焦虑症及相关障碍的效果。当前研究是一项随机对照试验，旨在确定EFT-T与等待名单对照在治疗抑郁症、焦虑症及相关障碍方面的疗效。在心理/咨询服务机构就诊的多达40名客户将被随机分配到两种情况：EFT-T组（n = 20）和等待名单对照组，后者延迟干预（n = 20）。主要结局指标将是总体焦虑严重程度和损害症状、总体抑郁严重程度和损害症状，以及常规评估中的临床结局——结局指标。特定障碍的自我报告测量也将用于评估各自主要诊断的主要症状。客户将在治疗前、第16周、治疗结束时以及6个月随访时接受评估。本研究旨在对EFT-T作为抑郁症、焦虑症及相关障碍的跨诊断治疗进行初步测试。它将提供效应量估计，可为比较EFT-T与标准跨诊断治疗CBT的对照试验的功效计算提供参考。国际标准随机对照试验编号：ISRCTN11430110；于2019年1月7日注册。
